Kidd & Company, LLC Exits NextPhase Medical Devices, LLC

Kidd & Company, LLC (“KCO”), a leading family office investment firm focused on the lower middle market, is pleased to announce the sale of NextPhase Medical Devices, LLC (“NextPhase”) to Medical Device, Inc. (“Arterex”), a leading medical device contract manufacturer, indirectly invested in by Investindustrial Growth fund. Terms of the transaction were not disclosed. NextPhase is a class II and III medical device contract manufacturer of complex electromechanical devices, active implantable devices and single use disposables in North America. It provides design and engineering, manufacturing and assembly, quality and regulatory, and supply chain and logistics management services enabling its customers to bring low-to-medium volume complex medical devices to market.

KCO initiated its investment in NextPhase in 2015 through a control investment in Nexcore Technology, which was founded by Milton Frank in 1999 as a manufacturer of complex electromechanical medical devices to leading medical OEMs. Upon completion of the initial platform acquisition, KCO added Carlo Colesanti and James DiVizio as NextPhase’s CEO and CFO, respectively, as well as made several investments and enhancements to the initial platform through additions to people, processes and infrastructure. In 2017 Nexcore acquired Phase 2 Medical Manufacturing and rebranded as NextPhase Medical Devices as a premier provider of design, engineering, development and manufacturing of capital equipment and single-use disposable devices to leading and emerging medical device OEMs. In 2021, NextPhase acquired Proven Process Medical Devices to enhance its design and engineering capabilities and to add specific manufacturing expertise in new areas, such as implantable devices. Today NextPhase operates out of three North American facilities in New Hampshire, Massachusetts and Tijuana, Mexico. For more information, visit www.nextphasemed.com.

Ken Heuer, KCO principal and NextPhase Board member stated, “We have been honored to work with Carlo, Jim, and each of the previous business owners and their respective organizations over the last eight years to generate tremendous growth, jobs and prosperity for everyone involved. We set out with the goal of building a comprehensive supply chain partner to the top medical device manufacturers and could not be happier with what the team has been able to achieve.” Carlo Colesanti added, “We appreciate the experience and resources that KCO brought to bear on behalf of the business and are excited for the next stage of our growth.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”